China expands reimbursement coverage for HUTCHMED's Elunate and Orpathys
HCM•China's updated National Reimbursement Drug List expands coverage for HUTCHMED's Elunate and Orpathys from January 1, 2027, including new combinations for eligible kidney and lung cancer patients.
1. Expanded coverage
China's updated National Reimbursement Drug List expands coverage for HUTCHMED's Elunate and Orpathys, effective January 1, 2027. Elunate gains coverage with sintilimab for eligible patients with previously treated, locally advanced or metastatic renal cell carcinoma.
2. Orpathys indications
Orpathys gains coverage with osimertinib for EGFR-mutated, MET-amplified advanced non-squamous lung cancer progressing on EGFR-targeted therapy. Coverage is renewed for Orpathys in MET exon 14-skipping lung cancer; other existing indications for Elunate, Orpathys and Sulanda remain covered.




